Some ideas to help you in daily practice
Breaking news from Day 4 of ESCRS
New approach to presbyopia treament
This is the first ESCRS congress for 9-month old company, Technolas, which was formed out of a joint venture between Bausch and Lomb's refractive surgery unit and 20/10 Perfect Vision. The new business was founded to innovate in excimer and femtosecond laser technologies, focusing primarily on the correction of presbyopia.
Help for surgeons with higher-resolution micro-endoscopes
Improved visualization of the eye&39;s anatomy is the aim of a new series of high-resolution micro-endoscopes from Endo Optiks.
Mobility is the key to corneal surgery
Ziemer has launched a new corneal surgery model to expand the capabilities of its LDV Femtosecond laser system.
Schwind PresbyMAX treats presbyopia with excimer surgery
Schwind unveiled its PresbyMAX software module at ESCRS, a presbyopia solution for its AMARIS system. According to Schwind, the software makes it possible, for the first time, to treat emmetropic as well as myopic, hyperopic and astigmatic patients whose accommodative response is limited.
More news from the congressBreakthrough micro-lens treatment for presbyopiaAlcon to acquire Swiss biotechnology businessToric IOL enhances refractive outcomes Improving retinal examination speed and efficiency Megatron S4 from Geuder delivers flexibility and mobilityThree steps to better toric surgeryA quartet of solutions for surgeonsAt the sharp endAn all in one optical biometer
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.
